{"protocolSection": {"identificationModule": {"nctId": "NCT02597049", "orgStudyIdInfo": {"id": "15361"}, "secondaryIdInfos": [{"id": "H9X-MC-GBGE", "type": "OTHER", "domain": "Eli Lilly and Company"}, {"id": "2015-002095-24", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Eli Lilly and Company", "class": "INDUSTRY"}, "briefTitle": "A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus", "officialTitle": "A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus", "acronym": "AWARD-10"}, "statusModule": {"statusVerifiedDate": "2020-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-11"}, "primaryCompletionDateStruct": {"date": "2017-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-11-03", "studyFirstSubmitQcDate": "2015-11-03", "studyFirstPostDateStruct": {"date": "2015-11-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-02-02", "resultsFirstSubmitQcDate": "2018-03-27", "resultsFirstPostDateStruct": {"date": "2018-04-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-06-10", "lastUpdatePostDateStruct": {"date": "2020-06-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Eli Lilly and Company", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 424, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1.5 mg Dulaglutide", "type": "EXPERIMENTAL", "description": "1.5 milligrams (mg) given subcutaneously (SC) once a week for 24 weeks.", "interventionNames": ["Drug: Dulaglutide", "Drug: SGLT2 inhibitor", "Drug: Metformin"]}, {"label": "0.75 mg Dulaglutide", "type": "EXPERIMENTAL", "description": "0.75 mg dulaglutide given SC once a week for 24 weeks.", "interventionNames": ["Drug: Dulaglutide", "Drug: SGLT2 inhibitor", "Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo given SC once a week for 24 weeks.", "interventionNames": ["Drug: Placebo", "Drug: SGLT2 inhibitor", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Dulaglutide", "description": "Administered SC", "armGroupLabels": ["0.75 mg Dulaglutide", "1.5 mg Dulaglutide"], "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Placebo", "description": "Administered SC", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "SGLT2 inhibitor", "description": "Administered orally as standard of care for type 2 diabetes", "armGroupLabels": ["0.75 mg Dulaglutide", "1.5 mg Dulaglutide", "Placebo"], "otherNames": ["Canagliflozin", "Dapagliflozin", "Empagliflozin"]}, {"type": "DRUG", "name": "Metformin", "description": "Administered orally as standard of care for type 2 diabetes", "armGroupLabels": ["0.75 mg Dulaglutide", "1.5 mg Dulaglutide", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand)", "description": "Least Squares mean (LS) of the HbA1c change from baseline to primary endpoint at week 24 was adjusted by treatment, country, SGLT2 inhibitor dose, metformin use, treatment-by-visit interactions as fixed effects, and baseline HbA1c as a covariate and participant as a random effect, via a MMRM analysis. The treatment-regimen estimand used all data including post-rescue data and compared the benefit of treatment regimens as they were actually taken.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand)", "description": "LS mean of the HbA1c change from baseline to primary endpoint at week 24 was adjusted by treatment, country, SGLT2 inhibitor dose, metformin use, treatment-by-visit interactions as fixed effects, and baseline HbA1c as a covariate and participant as a random effect, via a MMRM analysis. The efficacy estimand excluded post-rescue data and compared the benefit of randomized treatments when taken as directed without rescue medication.", "timeFrame": "Baseline, Week 24"}], "secondaryOutcomes": [{"measure": "Percentage of Participants With HbA1c <7%", "description": "Number of participants with an HbA1c value of \\<7% at Week 24 is measured using longitudinal logistic regression with repeated measurements. The model will include independent variables of treatment, country, SGLT2 inhibitor dose, metformin use, visit, treatment-by-visit interaction, and baseline HbA1c as a covariate.", "timeFrame": "24 Weeks"}, {"measure": "Change From Baseline in Body Weight at 24 Weeks", "description": "LS mean of the body weight change from baseline to primary endpoint at week 24 was adjusted by treatment, country, SGLT2 inhibitor dose, metformin use, baseline HbA1c strata, treatment-by-visit interactions as fixed effects, and baseline body weight as a covariate and participant as a random effect, via a MMRM analysis", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Serum Glucose (Central Laboratory) at 24 Weeks", "description": "LS mean of change from baseline was calculated using last observation carried forward (LOCF) by treatment group, adjusted for treatment, country, SGLT2 inhibitor dose, metformin use, baseline HbA1c strata, and baseline fasting serum glucose using analysis of covariance (ANCOVA).", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in 6-Point Self-Monitored Plasma Glucose (SMPG) Profile at 24 Weeks", "description": "The self-monitored plasma glucose (SMPG) data were collected at the following 6 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, metformin use, SGLT2 inhibitor use, country, visit, baseline HbA1c strata, and treatment-by-visit interaction as fixed effects and baseline as a covariate.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Glucagon at 24 Weeks", "description": "Change from baseline in fasting glucagon was analyzed using an ANCOVA model with last observation carried forward (LOCF) included in treatment, country, SGLT2i dose, metformin use, and baseline HbA1c strata as fixed effects and baseline fasting glucagon as a covariate (with and without post rescue data).", "timeFrame": "Baseline, Week 24"}, {"measure": "Rate of Hypoglycemic Events Adjusted Per 30 Days", "description": "A hypoglycemic event is defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a PG level of \u226470 mg/dL (\u22643.9 mmol/L).", "timeFrame": "Baseline through 24 Weeks"}, {"measure": "Number of Participants Requiring Rescue Therapy Due to Severe Persistent Hyperglycemia", "description": "Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation.", "timeFrame": "Baseline through 24 Weeks"}, {"measure": "Number of Participants With Adjudicated Acute Pancreatitis Events", "description": "The number of participants with events of pancreatitis confirmed by adjudication were summarized cumulatively at 24 weeks. Pancreatitis events were adjudicated by a committee of physicians external to the Sponsor.\n\nA summary of serious and other non-serious events regardless of causality is located in the Reported Adverse Events module.", "timeFrame": "Baseline through 24 Weeks"}, {"measure": "Number of Participants With Adjudicated Cardiovascular (CV) Events", "description": "Death and selected nonfatal CV adverse events (AEs) were adjudicated by an independent committee of physicians with cardiology expertise external to the Sponsor. Nonfatal CV events that were to be adjudicated were myocardial infarction (MI); hospitalization for unstable angina; hospitalization for heart failure; coronary interventions such as coronary artery bypass graft (CABG) or ( percutaneous coronary intervention (PCI); and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack (TIA).", "timeFrame": "Baseline through 24 Weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have type 2 diabetes mellitus (based on the World Health Organization's \\[WHO\\] diagnostic criteria)\n* Have been treated with an SGLT2 inhibitor, with or without metformin, for at least 3 months prior to study entry (minimum required doses for that period for allowed SGLT2 inhibitors: empagliflozin 10 mg, dapagliflozin 5 or 10 mg \\[per country-specific label\\], canagliflozin 100 mg); minimum required dose for metformin, if used, is \u22651500 mg/day and must be reached (or highest tolerated dose which is acceptable with documented gastrointestinal \\[GI\\] intolerability)\n* Daily doses of all allowed oral antihyperglycemia agent (OAMs) must have been stable for at least 12 weeks (\u00b13 days) prior to randomization (study enrollment); daily doses of SGLT2 inhibitor and metformin, if used, will be considered stable during this period if:\n\n  * all prescribed daily doses were in the range between the minimum required dose and maximum-approved dose per country-specific label; and\n  * \\>90% of prescribed daily doses were equal to the dose at randomization\n* Have HbA1c \u22657.0% and \u22649.5% at study entry and approximately 1 week prior to randomization\n* Have body mass index (BMI) \u226445 kilograms per meter squared (kg/m\\^2) and agree to not initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment\n\nExclusion Criteria:\n\n* Have type 1 diabetes mellitus\n* Have been treated with any other OAMs (other than SGLT2 inhibitors and metformin), glucagon-like peptide-1 receptor agonist (GLP-1 RA), pramlintide or insulin 3 months prior to study entry, or between study entry and randomization; or initiate metformin between study entry and randomization; short-term use of insulin for acute care (\u226414 days) during the 3-month period prior to entry is not exclusionary\n* Have any condition that is a contraindication for use of the GLP-1 RA class or the SGLT2 inhibitor class (per country-specific labels) at study entry or develop such condition between study entry and randomization\n* Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine transaminase (ALT) level \\>2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial\n* Had chronic or acute pancreatitis any time prior to study entry\n* Estimated glomerular filtration rate (eGFR) \\<45 milliliters(mL)/minute/1.73m\\^2, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, as determined by the central laboratory at study entry and confirmed at lead in\n* Have any self or family history of type 2A or type 2B multiple endocrine neoplasia (MEN 2A or 2B) in the absence of known C-cell hyperplasia (this exclusion includes participants with a family history of MEN 2A or 2B, whose family history for the syndrome is rearranged during transfect \\[RET\\]-negative; the only exception for this exclusion will be for participants whose family members with MEN 2A or 2B have a known RET mutation and the potential participant for the study is negative for the RET mutation)\n* Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, carcinoma (including sporadic, familial, or part of MEN 2A or 2B syndrome)\n* Have a serum calcitonin \u226520 picograms/mL as determined by the central laboratory at study entry", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "affiliation": "Eli Lilly and Company", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Medical Group of Encino", "city": "Encino", "state": "California", "zip": "91436", "country": "United States", "geoPoint": {"lat": 34.15917, "lon": -118.50119}}, {"facility": "National Research Institute", "city": "Huntington Park", "state": "California", "zip": "90255", "country": "United States", "geoPoint": {"lat": 33.98168, "lon": -118.22507}}, {"facility": "National Research Institute", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "New Horizon Research Center", "city": "Miami", "state": "Florida", "zip": "33175", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Metabolic Research Institute Inc.", "city": "West Palm Beach", "state": "Florida", "zip": "33401", "country": "United States", "geoPoint": {"lat": 26.71534, "lon": -80.05337}}, {"facility": "Cotton O'Neil Diabetes and Endocrinology Center", "city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "JCMG Clinical Research", "city": "Jefferson City", "state": "Missouri", "zip": "65109", "country": "United States", "geoPoint": {"lat": 38.5767, "lon": -92.17352}}, {"facility": "Grand Street Medical PC", "city": "Brooklyn", "state": "New York", "zip": "11211", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Diabetes & Endocrinology Consultants PC", "city": "Morehead City", "state": "North Carolina", "zip": "28557", "country": "United States", "geoPoint": {"lat": 34.72294, "lon": -76.72604}}, {"facility": "PMG Research of Wilmington, LLC", "city": "Wilmington", "state": "North Carolina", "zip": "28401", "country": "United States", "geoPoint": {"lat": 34.22573, "lon": -77.94471}}, {"facility": "Dallas Diabetes Endocrine Center", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Galenos Research", "city": "Dallas", "state": "Texas", "zip": "75251", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Endeavor Clinical Trials", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Saint Stefan Ob Stainz", "zip": "8511", "country": "Austria"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Steyr", "zip": "4400", "country": "Austria", "geoPoint": {"lat": 48.04274, "lon": 14.42127}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Wien", "zip": "1030", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician", "city": "Brandys Nad Labem-Stara Bolesl", "zip": "25001", "country": "Czechia"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Holesov", "zip": "769 01", "country": "Czechia", "geoPoint": {"lat": 49.33331, "lon": 17.57832}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Krnov", "zip": "79401", "country": "Czechia", "geoPoint": {"lat": 50.08967, "lon": 17.70385}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Pardubice", "zip": "53002", "country": "Czechia", "geoPoint": {"lat": 50.04075, "lon": 15.77659}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Praha 4", "zip": "149 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Praha 8", "zip": "181 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "M\u00fcnster", "zip": "48145", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Oldenburg", "zip": "23758", "country": "Germany", "geoPoint": {"lat": 53.14118, "lon": 8.21467}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Budapest", "zip": "1023", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Budapest", "zip": "1042", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Debrecen", "zip": "4043", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nagykanizsa", "zip": "8800", "country": "Hungary", "geoPoint": {"lat": 46.45347, "lon": 16.99104}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Haifa", "zip": "3299001", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Holon", "zip": "5822012", "country": "Israel", "geoPoint": {"lat": 32.01034, "lon": 34.77918}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Jerusalem", "zip": "911200", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Monterrey", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Monterrey", "zip": "64620", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Zapopan", "zip": "45116", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "Centro de Endocrinologia y Nutricion", "city": "Caguas", "zip": "00725", "country": "Puerto Rico", "geoPoint": {"lat": 18.23412, "lon": -66.0485}}, {"facility": "Manati Medical Center", "city": "Manati", "zip": "00674", "country": "Puerto Rico", "geoPoint": {"lat": 18.42745, "lon": -66.49212}}, {"facility": "Centro de Endocrinologia del Este", "city": "Yabucoa", "zip": "00767", "country": "Puerto Rico", "geoPoint": {"lat": 18.05052, "lon": -65.87933}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Alicante", "zip": "03004", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Malaga", "zip": "29006", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sevilla", "zip": "41003", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seville", "zip": "41010", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}]}, "referencesModule": {"references": [{"pmid": "29483060", "type": "DERIVED", "citation": "Ludvik B, Frias JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, Garcia-Perez LE, Woodward DB, Milicevic Z. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018 May;6(5):370-381. doi: 10.1016/S2213-8587(18)30023-8. Epub 2018 Feb 23. Erratum In: Lancet Diabetes Endocrinol. 2018 Jun;6(6):e5. doi: 10.1016/S2213-8587(18)30152-9."}], "seeAlsoLinks": [{"label": "Click here for more information about this study: A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus", "url": "http://www.lillytrialguide.com/EN-US/studies/diabetes/gbge"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"], "timeFrame": "Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.", "accessCriteria": "A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.", "url": "https://vivli.org/"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 milligrams (mg) given SC QW for 24 weeks."}, {"id": "FG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 mg given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "FG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "142"}, {"groupId": "FG001", "numSubjects": "142"}, {"groupId": "FG002", "numSubjects": "140"}]}, {"type": "Received at Least One Dose of Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "142"}, {"groupId": "FG001", "numSubjects": "141"}, {"groupId": "FG002", "numSubjects": "140"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "135"}, {"groupId": "FG001", "numSubjects": "137"}, {"groupId": "FG002", "numSubjects": "137"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Noncompliant with Study Visits", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized participants who received at least one dose of study drug.", "groups": [{"id": "BG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 milligrams (mg) given SC QW for 24 weeks."}, {"id": "BG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 mg given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "BG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "56.17", "spread": "9.26"}, {"groupId": "BG001", "value": "58.55", "spread": "9.14"}, {"groupId": "BG002", "value": "57.10", "spread": "9.59"}, {"groupId": "BG003", "value": "57.27", "spread": "9.36"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "65"}, {"groupId": "BG001", "value": "72"}, {"groupId": "BG002", "value": "74"}, {"groupId": "BG003", "value": "211"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "77"}, {"groupId": "BG001", "value": "69"}, {"groupId": "BG002", "value": "66"}, {"groupId": "BG003", "value": "212"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "44"}, {"groupId": "BG003", "value": "139"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "90"}, {"groupId": "BG001", "value": "97"}, {"groupId": "BG002", "value": "94"}, {"groupId": "BG003", "value": "281"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "3"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "7"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "12"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "127"}, {"groupId": "BG002", "value": "124"}, {"groupId": "BG003", "value": "378"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "25"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "Austria", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "29"}]}]}, {"title": "Hungary", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "57"}]}]}, {"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "88"}]}]}, {"title": "Czechia", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "25"}, {"groupId": "BG003", "value": "73"}]}]}, {"title": "Mexico", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "83"}]}]}, {"title": "Israel", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "18"}]}]}, {"title": "Germany", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "33"}]}]}, {"title": "Spain", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "142"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "140"}, {"groupId": "BG003", "value": "423"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "42"}]}]}]}, {"title": "Baseline Mean Hemoglobin A1c (HbA1c) Treatment-Regimen Estimand", "populationDescription": "All randomized participants who received at least one dose of study drug and had a baseline measure of HbA1c.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of HbA1c", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "140"}, {"groupId": "BG001", "value": "139"}, {"groupId": "BG002", "value": "137"}, {"groupId": "BG003", "value": "416"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8.04", "spread": "0.66"}, {"groupId": "BG001", "value": "8.04", "spread": "0.61"}, {"groupId": "BG002", "value": "8.05", "spread": "0.66"}, {"groupId": "BG003", "value": "8.04", "spread": "0.64"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand)", "description": "Least Squares mean (LS) of the HbA1c change from baseline to primary endpoint at week 24 was adjusted by treatment, country, SGLT2 inhibitor dose, metformin use, treatment-by-visit interactions as fixed effects, and baseline HbA1c as a covariate and participant as a random effect, via a MMRM analysis. The treatment-regimen estimand used all data including post-rescue data and compared the benefit of treatment regimens as they were actually taken.", "populationDescription": "All randomized participants who received at least one dose of study medication and had evaluable data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 mg given SC QW for 24 weeks."}, {"id": "OG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 milligrams (mg) given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "134"}, {"groupId": "OG002", "value": "133"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.34", "spread": "0.064"}, {"groupId": "OG001", "value": "-1.21", "spread": "0.064"}, {"groupId": "OG002", "value": "-0.54", "spread": "0.064"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.97", "ciUpperLimit": "-0.61"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.84", "ciUpperLimit": "-0.49"}]}, {"type": "PRIMARY", "title": "Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand)", "description": "LS mean of the HbA1c change from baseline to primary endpoint at week 24 was adjusted by treatment, country, SGLT2 inhibitor dose, metformin use, treatment-by-visit interactions as fixed effects, and baseline HbA1c as a covariate and participant as a random effect, via a MMRM analysis. The efficacy estimand excluded post-rescue data and compared the benefit of randomized treatments when taken as directed without rescue medication.", "populationDescription": "All randomized participants who received at least one dose of study drug and had a baseline and post-baseline value excluding values collected after rescue medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 mg given SC QW for 24 weeks."}, {"id": "OG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 milligrams (mg) given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "131"}, {"groupId": "OG002", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.33", "spread": "0.063"}, {"groupId": "OG001", "value": "-1.19", "spread": "0.063"}, {"groupId": "OG002", "value": "-0.51", "spread": "0.065"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.82", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.00", "ciUpperLimit": "-0.64"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.69", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.86", "ciUpperLimit": "-0.51"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With HbA1c <7%", "description": "Number of participants with an HbA1c value of \\<7% at Week 24 is measured using longitudinal logistic regression with repeated measurements. The model will include independent variables of treatment, country, SGLT2 inhibitor dose, metformin use, visit, treatment-by-visit interaction, and baseline HbA1c as a covariate.", "populationDescription": "All participants who received at least one dose of Dulaglutide with HbA1c \\<7% at Week 24.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "24 Weeks", "groups": [{"id": "OG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 mg given SC QW for 24 weeks."}, {"id": "OG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 milligrams (mg) given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "140"}]}], "classes": [{"title": "Treatment-regimen Estimand", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "134"}, {"groupId": "OG002", "value": "133"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "71.21"}, {"groupId": "OG001", "value": "60.45"}, {"groupId": "OG002", "value": "31.58"}]}]}, {"title": "Efficacy Estimand", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}, {"groupId": "OG001", "value": "131"}, {"groupId": "OG002", "value": "123"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "71.54"}, {"groupId": "OG001", "value": "61.83"}, {"groupId": "OG002", "value": "32.52"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Treatment-regimen Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Regression, Logistic"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Treatment-regimen Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Regression, Logistic"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Efficacy Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Regression, Logistic"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Efficacy Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Regression, Logistic"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at 24 Weeks", "description": "LS mean of the body weight change from baseline to primary endpoint at week 24 was adjusted by treatment, country, SGLT2 inhibitor dose, metformin use, baseline HbA1c strata, treatment-by-visit interactions as fixed effects, and baseline body weight as a covariate and participant as a random effect, via a MMRM analysis", "populationDescription": "All participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilograms (kg)", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 mg given SC QW for 24 weeks."}, {"id": "OG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 milligrams (mg) given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "140"}]}], "classes": [{"title": "Treatment-regimen Estimand", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "136"}, {"groupId": "OG002", "value": "137"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.1", "spread": "0.30"}, {"groupId": "OG001", "value": "-2.6", "spread": "0.30"}, {"groupId": "OG002", "value": "-2.1", "spread": "0.30"}]}]}, {"title": "Efficacy Estimand", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "133"}, {"groupId": "OG001", "value": "133"}, {"groupId": "OG002", "value": "127"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.1", "spread": "0.30"}, {"groupId": "OG001", "value": "-2.6", "spread": "0.30"}, {"groupId": "OG002", "value": "-2.3", "spread": "0.31"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Treatment-regimen Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "0.027", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.8", "ciUpperLimit": "-0.1"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Treatment-regimen Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "0.264", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.3", "ciUpperLimit": "0.4"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Efficacy Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "0.059", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.7", "ciUpperLimit": "0.0"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Efficacy Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "0.435", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.2", "ciUpperLimit": "0.5"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Serum Glucose (Central Laboratory) at 24 Weeks", "description": "LS mean of change from baseline was calculated using last observation carried forward (LOCF) by treatment group, adjusted for treatment, country, SGLT2 inhibitor dose, metformin use, baseline HbA1c strata, and baseline fasting serum glucose using analysis of covariance (ANCOVA).", "populationDescription": "All participants who received at least one dose of study drug and had baseline and at least one post-baseline value.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "milligram/deciliter (mg/dL)", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 mg given SC QW for 24 weeks."}, {"id": "OG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 milligrams (mg) given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "140"}]}], "classes": [{"title": "Treatment-regimen Estimand", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "134"}, {"groupId": "OG001", "value": "133"}, {"groupId": "OG002", "value": "132"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.6", "spread": "2.17"}, {"groupId": "OG001", "value": "-26.5", "spread": "2.18"}, {"groupId": "OG002", "value": "-6.9", "spread": "2.21"}]}]}, {"title": "Efficacy Estimand", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "132"}, {"groupId": "OG001", "value": "130"}, {"groupId": "OG002", "value": "122"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.9", "spread": "2.11"}, {"groupId": "OG001", "value": "-26.0", "spread": "2.12"}, {"groupId": "OG002", "value": "-5.3", "spread": "2.21"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Treatment-regimen Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-24.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.8", "ciUpperLimit": "-18.6"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Treatment-regimen Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "pValueComment": "Test was not controlled for type I error.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-19.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.7", "ciUpperLimit": "-13.5"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Efficacy Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "pValueComment": "Test was not controlled for type I error.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-26.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-32.7", "ciUpperLimit": "-20.6"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Efficacy Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "pValueComment": "Test was not controlled for type I error.", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-20.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.7", "ciUpperLimit": "-14.6"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 6-Point Self-Monitored Plasma Glucose (SMPG) Profile at 24 Weeks", "description": "The self-monitored plasma glucose (SMPG) data were collected at the following 6 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, metformin use, SGLT2 inhibitor use, country, visit, baseline HbA1c strata, and treatment-by-visit interaction as fixed effects and baseline as a covariate.", "populationDescription": "All participants who received at least one dose of study drug and had baseline SMPG value and at least one post-baseline SMPG value.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 mg given SC QW for 24 weeks."}, {"id": "OG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 milligrams (mg) given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "140"}]}], "classes": [{"title": "Pre-morning Morning Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "124"}, {"groupId": "OG002", "value": "128"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.8", "spread": "2.13"}, {"groupId": "OG001", "value": "-23.2", "spread": "2.17"}, {"groupId": "OG002", "value": "-8.1", "spread": "2.14"}]}]}, {"title": "2-Hour Postprandial Morning Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "119"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-44.6", "spread": "3.31"}, {"groupId": "OG001", "value": "-41.1", "spread": "3.30"}, {"groupId": "OG002", "value": "-20.1", "spread": "3.33"}]}]}, {"title": "Pre-Mid Day Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "124"}, {"groupId": "OG002", "value": "126"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-26.0", "spread": "2.91"}, {"groupId": "OG001", "value": "-22.0", "spread": "2.94"}, {"groupId": "OG002", "value": "-7.7", "spread": "2.93"}]}]}, {"title": "2-Hour Postprandial Mid Day Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "118"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-31.8", "spread": "3.47"}, {"groupId": "OG001", "value": "-25.5", "spread": "3.47"}, {"groupId": "OG002", "value": "-12.8", "spread": "3.53"}]}]}, {"title": "Pre-Evening Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "124"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-30.3", "spread": "2.85"}, {"groupId": "OG001", "value": "-30.1", "spread": "2.93"}, {"groupId": "OG002", "value": "-7.5", "spread": "2.91"}]}]}, {"title": "2-Hour Postprandial Evening Meal", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "122"}, {"groupId": "OG001", "value": "121"}, {"groupId": "OG002", "value": "117"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-36.0", "spread": "3.30"}, {"groupId": "OG001", "value": "-30.6", "spread": "3.31"}, {"groupId": "OG002", "value": "-13.9", "spread": "3.38"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Pre-morning meal.", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-19.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-25.7", "ciUpperLimit": "-13.8"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Pre-morning meal", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-15.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.2", "ciUpperLimit": "-9.2"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "2-hour postprandial", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-24.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-33.8", "ciUpperLimit": "-15.3"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "2-hour postprandial", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-21.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.3", "ciUpperLimit": "-11.8"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Pre-midday meal", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-18.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.4", "ciUpperLimit": "-10.2"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Pre-midday meal", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-14.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-22.5", "ciUpperLimit": "-6.2"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "2-hour postprandial after midday meal", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-19.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.8", "ciUpperLimit": "-9.3"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "2-hour postprandial after midday meal", "nonInferiorityType": "SUPERIORITY", "pValue": "0.010", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-12.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-22.5", "ciUpperLimit": "-3.1"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Pre-evening meal", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-22.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.7", "ciUpperLimit": "-14.7"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Pre-evening meal", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-22.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.7", "ciUpperLimit": "-14.4"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "2-hour postprandial after evening meal", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-22.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-31.4", "ciUpperLimit": "-12.9"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "2-hour postprandial after evening meal", "nonInferiorityType": "SUPERIORITY", "pValue": "< .001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-16.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.0", "ciUpperLimit": "-7.4"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Glucagon at 24 Weeks", "description": "Change from baseline in fasting glucagon was analyzed using an ANCOVA model with last observation carried forward (LOCF) included in treatment, country, SGLT2i dose, metformin use, and baseline HbA1c strata as fixed effects and baseline fasting glucagon as a covariate (with and without post rescue data).", "populationDescription": "All participants who received at least one dose of study drug and with non-missing baseline values and at least one post-baseline value at the specified time point.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "picomole per liter (pmol/L)", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 mg given SC QW for 24 weeks."}, {"id": "OG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 milligrams (mg) given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "140"}]}], "classes": [{"title": "Treatment-regimen Estimand", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "140"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.1", "spread": "0.39"}, {"groupId": "OG001", "value": "-1.5", "spread": "0.39"}, {"groupId": "OG002", "value": "-0.9", "spread": "0.40"}]}]}, {"title": "Efficacy Estimand", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "133"}, {"groupId": "OG001", "value": "129"}, {"groupId": "OG002", "value": "118"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.2", "spread": "0.39"}, {"groupId": "OG001", "value": "-1.4", "spread": "0.39"}, {"groupId": "OG002", "value": "-0.9", "spread": "0.41"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Treatment-regimen Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "0.032", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.3", "ciUpperLimit": "-0.1"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Treatment-regimen Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "0.273", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.7", "ciUpperLimit": "0.5"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Efficacy Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "0.023", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.4", "ciUpperLimit": "-0.2"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Efficacy Estimand", "nonInferiorityType": "SUPERIORITY", "pValue": "0.320", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.7", "ciUpperLimit": "0.6"}]}, {"type": "SECONDARY", "title": "Rate of Hypoglycemic Events Adjusted Per 30 Days", "description": "A hypoglycemic event is defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a PG level of \u226470 mg/dL (\u22643.9 mmol/L).", "populationDescription": "All participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of events/participant/30 days", "timeFrame": "Baseline through 24 Weeks", "groups": [{"id": "OG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 mg given SC QW for 24 weeks."}, {"id": "OG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 milligrams (mg) given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "140"}]}], "classes": [{"title": "Total Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.026", "spread": "0.1827"}, {"groupId": "OG001", "value": "0.022", "spread": "0.1375"}, {"groupId": "OG002", "value": "0.017", "spread": "0.1320"}]}]}, {"title": "Documented Symptomatic Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.013", "spread": "0.1406"}, {"groupId": "OG001", "value": "0.013", "spread": "0.1030"}, {"groupId": "OG002", "value": "0.010", "spread": "0.0893"}]}]}, {"title": "Asymptomatic Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.013", "spread": "0.1180"}, {"groupId": "OG001", "value": "0.008", "spread": "0.0639"}, {"groupId": "OG002", "value": "0.006", "spread": "0.0540"}]}]}, {"title": "Probable Symptomatic", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.000", "spread": "0.0000"}, {"groupId": "OG001", "value": "0.001", "spread": "0.0152"}, {"groupId": "OG002", "value": "0.001", "spread": "0.0147"}]}]}, {"title": "Relative Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.003", "spread": "0.0311"}, {"groupId": "OG001", "value": "0.001", "spread": "0.0150"}, {"groupId": "OG002", "value": "0.005", "spread": "0.0493"}]}]}, {"title": "Nocturnal Hypoglycemia", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.002", "spread": "0.0288"}, {"groupId": "OG001", "value": "0.009", "spread": "0.0821"}, {"groupId": "OG002", "value": "0.000", "spread": "0.0000"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Requiring Rescue Therapy Due to Severe Persistent Hyperglycemia", "description": "Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation.", "populationDescription": "All participants who had at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "timeFrame": "Baseline through 24 Weeks", "groups": [{"id": "OG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 mg given SC QW for 24 weeks."}, {"id": "OG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 milligrams (mg) given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "140"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adjudicated Acute Pancreatitis Events", "description": "The number of participants with events of pancreatitis confirmed by adjudication were summarized cumulatively at 24 weeks. Pancreatitis events were adjudicated by a committee of physicians external to the Sponsor.\n\nA summary of serious and other non-serious events regardless of causality is located in the Reported Adverse Events module.", "populationDescription": "All participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "timeFrame": "Baseline through 24 Weeks", "groups": [{"id": "OG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 mg given SC QW for 24 weeks."}, {"id": "OG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 milligrams (mg) given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "140"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adjudicated Cardiovascular (CV) Events", "description": "Death and selected nonfatal CV adverse events (AEs) were adjudicated by an independent committee of physicians with cardiology expertise external to the Sponsor. Nonfatal CV events that were to be adjudicated were myocardial infarction (MI); hospitalization for unstable angina; hospitalization for heart failure; coronary interventions such as coronary artery bypass graft (CABG) or ( percutaneous coronary intervention (PCI); and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack (TIA).", "populationDescription": "All participants who received at least one dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "timeFrame": "Baseline through 24 Weeks", "groups": [{"id": "OG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 mg given SC QW for 24 weeks."}, {"id": "OG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 milligrams (mg) given subcutaneously (SC) once a week (QW) for 24 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "140"}]}], "classes": [{"title": "Any CV Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Fatal CV Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Non-fatal CV Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Baseline to end of study (up to 24 weeks)", "description": "All participants who received at least one dose of study drug.", "eventGroups": [{"id": "EG000", "title": "1.5 mg Dulaglutide", "description": "Dulaglutide 1.5 milligrams (mg) given SC QW for 24 weeks.", "deathsNumAffected": 2, "deathsNumAtRisk": 142, "seriousNumAffected": 5, "seriousNumAtRisk": 142, "otherNumAffected": 43, "otherNumAtRisk": 142}, {"id": "EG001", "title": "0.75 mg Dulaglutide", "description": "Dulaglutide 0.75 mg given subcutaneously (SC) once a week (QW) for 24 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 141, "seriousNumAffected": 3, "seriousNumAtRisk": 141, "otherNumAffected": 34, "otherNumAtRisk": 141}, {"id": "EG002", "title": "Placebo", "description": "Placebo given SC QW for 24 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 140, "seriousNumAffected": 5, "seriousNumAtRisk": 140, "otherNumAffected": 29, "otherNumAtRisk": 140}], "seriousEvents": [{"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 140}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 140}]}, {"term": "Atrial tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 140}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 140}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}]}, {"term": "Clostridium difficile colitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}]}, {"term": "Erysipelas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 140}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}]}, {"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 140}]}, {"term": "Spinal cord injury lumbar", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}]}, {"term": "Endometrial cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}]}, {"term": "Endometrial sarcoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 74}]}, {"term": "Malignant neoplasm of conjunctiva", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 77}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 66}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 140}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 8, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 16, "numAffected": 14, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 140}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 32, "numAffected": 21, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 13, "numAffected": 7, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 6, "numAffected": 5, "numAtRisk": 140}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 9, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 10, "numAffected": 8, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 12, "numAffected": 11, "numAtRisk": 140}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 13, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 14, "numAffected": 12, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 14, "numAffected": 10, "numAtRisk": 140}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 8, "numAtRisk": 142}, {"groupId": "EG001", "numEvents": 8, "numAffected": 5, "numAtRisk": 141}, {"groupId": "EG002", "numEvents": 16, "numAffected": 13, "numAtRisk": 140}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "One participant was randomized into the study but did not receive study drug. This participant was not included in the efficacy or safety analysis."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Chief Medical Officer", "organization": "Eli Lilly and Company", "email": "ClinicalTrials.gov@lilly.com", "phone": "800-545-5979"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol: GBGE (a) Protocol", "date": "2015-08-21", "uploadDate": "2018-02-02T16:09", "filename": "Prot_000.pdf", "size": 2138621}, {"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol: GBGE (b) Protocol", "date": "2016-03-28", "uploadDate": "2018-02-02T16:10", "filename": "Prot_001.pdf", "size": 2000542}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2016-04-01", "uploadDate": "2018-02-02T16:11", "filename": "SAP_002.pdf", "size": 948056}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000529054", "term": "Dapagliflozin"}, {"id": "C000570240", "term": "Empagliflozin"}, {"id": "D000068896", "term": "Canagliflozin"}, {"id": "C000555680", "term": "Dulaglutide"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000097789", "term": "Glucagon-Like Peptide-1 Receptor Agonists"}], "browseLeaves": [{"id": "M258082", "name": "Empagliflozin", "asFound": "Peer", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M348449", "name": "Dapagliflozin", "asFound": "Body weight", "relevance": "HIGH"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "asFound": "Non-specific", "relevance": "HIGH"}, {"id": "M258626", "name": "Dulaglutide", "asFound": "Clostridium", "relevance": "HIGH"}, {"id": "M331", "name": "Canagliflozin", "asFound": "Nasopharyngeal", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M9043", "name": "Glucagon", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}]}}, "hasResults": true}